WallStreetZenWallStreetZen

NASDAQ: CSCI
Cosciens Biopharma Revenue

OverviewEarningsRevenue
DividendOwnership
Cosciens Biopharma revenue was $9.59M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $3.3M, up 77.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CSCI annual revenue was $9.6M, with 34.2% growth year-over-year.

CSCI past revenue growth

How has CSCI's revenue growth performed historically?

Company
34.22%
Industry
497.69%
Market
20.68%
CSCI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CSCI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CSCI's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CSCI revenue history

Current Revenue
$9.6M
Current Earnings
-$15.3M
Current Profit Margin
-159.7%

Be the first to know when CSCI announces revenue.

CSCI Revenue History By Year

CSCI Yearly RevenueCSCI RevenueCSCI ChangeCSCI Revenue Growth
2024-12-31$9.59M$2.44M+34.22%
2023-12-31$7.14M-$7.43M-50.98%
2022-12-31$14.57M$9.31M+177.03%
2021-12-31$5.26M$1.61M+44.03%
2020-12-31$3.65M$3.12M+586.47%
2019-12-31$532.00k-$26.35M-98.02%
2018-12-31$26.88M$25.96M+2,812.35%
2017-12-31$923.00k$12.00k+1.32%
2016-12-31$911.00k$366.00k+67.16%
2015-12-31$545.00k$534.00k+4,854.55%
2014-12-31$11.00k-$6.16M-99.82%
2013-12-31$6.18M$4.12M+200.78%
2012-12-31$2.05M-$2.65M-56.37%
2011-12-31$4.71M-$23.00M-83.02%
2010-12-31$27.70M-$35.53M-56.19%
2009-12-31$63.24M$24.76M+64.35%
2008-12-31$38.48M-$3.59M-8.53%
2007-12-31$42.07M$3.27M+8.43%
2006-12-31$38.80M-$6.01M-13.42%
2005-12-31$44.81M$1.84M+4.28%
2004-12-31$42.97M-$75.77M-63.81%
2003-12-31$118.74M$40.81M+52.37%
2002-12-31$77.93M$44.22M+131.18%
2001-12-31$33.71M$27.24M+420.84%
2000-12-31$6.47M$1.73M+36.49%
1999-12-31$4.74MN/AN/A

1 of 2

Cosciens Biopharma Revenue FAQ

What was CSCI's revenue last quarter?

On Invalid Date, Cosciens Biopharma (NASDAQ: CSCI) reported Q4 2024 revenue of $3.32 million up 173.64% year over year. In the same quarter last year, Cosciens Biopharma's revenue was $1.21 million.

What was Cosciens Biopharma's revenue in 2024?

Cosciens Biopharma's annual revenue for the twelve months ending Dec 31, 2024 was $9.59 million, a 34.22% increase year over year.

How much does Cosciens Biopharma make in a day?

Based on Cosciens Biopharma annual revenue for the past five years, CSCI makes an average of $22,035.07 per day.

What was Cosciens Biopharma's annual revenue growth in the past year?

As of Q2 2025, Cosciens Biopharma's revenue has grown 34.22% year over year. This is 463.48 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Cosciens Biopharma's revenue in the past year totaled $9.59 million.

How much does Cosciens Biopharma make in a year?

Cosciens Biopharma's revenue by year for the past five years is:
  • Cosciens Biopharma's revenue for the twelve months ending Dec 31, 2024 was $9.59 million, a 34.22% increase year over year.
  • Cosciens Biopharma's annual revenue for Dec 31, 2023 was $7.14 million, a 50.98% decrease from 2022.
  • Cosciens Biopharma's annual revenue for 2022 was $14.57 million, a 177.03% increase from 2021.
  • Cosciens Biopharma's annual revenue for 2021 was $5.26 million, a 44.03% increase from 2020.
  • Cosciens Biopharma's annual revenue for 2020 was $3.65 million, a 586.47% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.